104 related articles for article (PubMed ID: 35661563)
1. Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters.
Conte WL; Golzarri-Arroyo L
Mult Scler Relat Disord; 2022 Jul; 63():103905. PubMed ID: 35661563
[TBL] [Abstract][Full Text] [Related]
2. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
[TBL] [Abstract][Full Text] [Related]
3. Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study.
Nassar MK; Sabry A; Elgamal M; Zeid Z; Abdellateif Abdelghany D; Tharwat S
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138212
[No Abstract] [Full Text] [Related]
4. Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder.
Stastna D; Vachova M; Dusek P; Fistravec G; Drahota J; Menkyova I; Varju E; Horakova D; Kubala Havrdova E; Nytrova P
Mult Scler Relat Disord; 2024 May; 85():105523. PubMed ID: 38452649
[TBL] [Abstract][Full Text] [Related]
5. Response to mRNA SARS-CoV-2 vaccination evaluated by B-cell receptor repertoire after tixagevimab/cilgavimab administration.
Funakoshi Y; Yakushijin K; Ohji G; Matsutani T; Hojo W; Sakai H; Matsumoto S; Watanabe M; Kitao A; Saito Y; Kawamoto S; Yamamoto K; Koyama T; Nagatani Y; Kimbara S; Imamura Y; Kiyota N; Ito M; Minami H
Br J Haematol; 2023 Aug; 202(3):504-516. PubMed ID: 37349876
[TBL] [Abstract][Full Text] [Related]
6. Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?
Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Svizzeretto E; Tommasi A; Pallotto C; Schiaroli E; Francisci D
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543720
[TBL] [Abstract][Full Text] [Related]
7. Tixagevimab/cilgavimab for the prevention of COVID-19 in vaccine-refractory patients with autoimmune diseases: a prospective cohort study.
Minopoulou I; Tascilar K; Corte G; Mutlu MY; Schmidt K; Bohr D; Hartmann F; Manger K; Manger B; Korn K; Kleyer A; Simon D; Harrer T; Schett G; Fagni F
Rheumatology (Oxford); 2024 May; 63(5):1377-1383. PubMed ID: 37531288
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis.
Glhoom S; Fergany A; El-Araby D; Abdelkhalek AA; Gomaa A; Zayed EO; Abd-ElGwad M
Eur J Med Res; 2024 Jan; 29(1):27. PubMed ID: 38183123
[TBL] [Abstract][Full Text] [Related]
9. A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment.
Focosi D; Casadevall A
Viruses; 2022 Sep; 14(9):. PubMed ID: 36146805
[TBL] [Abstract][Full Text] [Related]
10. Tixagevimab/Cilgavimab does not prevent COVID-19 in patients with multiple sclerosis and related disorders on B-cell depleting therapies.
Conway S; Gupta S; Healy B; Chuang TY; Stazzone L; Sullivan J; Polgar-Turcsanyi M; Chitnis T; Houtchens M
Mult Scler Relat Disord; 2024 Jul; 87():105680. PubMed ID: 38795595
[TBL] [Abstract][Full Text] [Related]
11. Tixagevimab/cilgavimab (AZD7442/Evusheld) prevent from COVID19 in patients with hematologic malignancies under active chemotherapy.
Lee YJ; Kim HK; Kim Y; Park SH; Lim JH; Jung J; Choi YS; Jo JC
Ann Hematol; 2024 Apr; ():. PubMed ID: 38678486
[TBL] [Abstract][Full Text] [Related]
12. Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience.
Akinosoglou K; Rigopoulos EA; Kaiafa G; Daios S; Karlafti E; Ztriva E; Polychronopoulos G; Gogos C; Savopoulos C
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680160
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience.
Pulvirenti F; Garzi G; Milito C; Sculco E; Sciannamea M; Napoli A; Cinti L; Roberto P; Punziano A; Carrabba M; Piano Mortari E; Carsetti R; Antonelli G; Quinti I
Front Immunol; 2023; 14():1249462. PubMed ID: 37954618
[TBL] [Abstract][Full Text] [Related]
14. Real-World Efficacy of COVID-19 Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab in People with Multiple Sclerosis.
Elias LB; Jaber A; Manzano M; Leekoff M; Sylvester A; Tremblay MA
Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140258
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tixagevimab-cilgavimab (Evusheld®) in people with Multiple Sclerosis on Ocrelizumab: preliminary evidence.
Altieri M; Melisi RD; Conte M; Capuano R; Donnarumma G; Grimaldi E; Coppola N; De Pascalis S; Risi M; d'Ambrosio A; Bisecco A; Gallo A
Neurol Sci; 2023 Nov; 44(11):4107-4110. PubMed ID: 37498399
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies.
Reimann P; Petzer V; Mündlein A; Hartmann B; Severgnini L; Winkler A; Lang T; Huynh M; Gasser K; Rüger J; Atzl M; Mink S; Fraunberger P; Schmidt S; Steiner N; Griesmacher A; Gunsilius E; Nachbaur D; Willenbacher W; Wolf D; Winder T; Benda MA
Ann Hematol; 2024 Jun; 103(6):2123-2131. PubMed ID: 38436671
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study.
Demel I; Skopal D; Šafránková E; Rozsívalová P; Jindra P; Šrámek J; Turková A; Vydra J; Labská K; Vedrová J; Čerňan M; Szotkowski T; Móciková H; Hynková L; Šušol O; Kováčová I; Belada D; Hájek R
Ann Hematol; 2024 Mar; 103(3):981-992. PubMed ID: 38092996
[TBL] [Abstract][Full Text] [Related]
18. Tixagevimab-Cilgavimab Decreases the Rate of SARS-CoV-2 Infection Among Solid Organ Transplant Recipients.
Sanayei AM; Montalvan A; Faria I; Ochalla J; Pavlakis M; Blair BM; Alonso CD; Curry M; Saberi B
Transplant Proc; 2023 Oct; 55(8):1784-1792. PubMed ID: 37661468
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions.
Duminuco A; Nardo A; Orofino A; Giunta G; Conticello C; Del Fabro V; Chiarenza A; Parisi MS; Figuera A; Leotta S; Milone G; Cupri A; Cambria D; Di Raimondo F; Romano A; Palumbo GA
Cancer; 2024 Jan; 130(1):41-50. PubMed ID: 37658645
[TBL] [Abstract][Full Text] [Related]
20. Nephrotic-range proteinuria: a potential risk factor for failure of tixagevimab-cilgavimab prophylaxis.
Al Jurdi A; El Mouhayyar C; Efe O; Jeyabalan A; Riella LV
J Nephrol; 2024 Jan; 37(1):141-147. PubMed ID: 37658973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
